Clinical trials: Non-Communicable Chronic Diseases
Hepatitis C, Hepatitis B
Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound
Liver fibrosis is an important public health problem, with a substantial morbidity and mortality due to progression to cirrhosis and hepatocellular carcinoma. All causes of chronic liver disease may lead to fibrosis.
- Conditions
- Hepatitis C, Hepatitis B, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
- Trial name
- ELF (NCT02044523)
- Testing
- Transient elastography, acoustic radiation force impulse, magnetic resonance elastography
- Where
- Canada
- Volunteers
- 108 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Hepatitis C, Chronic
Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon
Title Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin with or without Interferon among Pakistani Population: A real life trial Hepatitis Eradication Accuracy Trial of Sofosbuvir (HEATS) Study Design Endpoint…
- Trial name
- HEATS (NCT02804386)
- Testing
- Sofosbuvir
- Where
- Pakistan
- Volunteers
- 573 people
- Sponsor
- PharmEvo Pvt Ltd
Chronic Hepatitis C, HCV
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
The purpose of this study is to assess the safety and efficacy of 12 weeks of treatment of ABT-493/ABT-530 (glecaprevir/pibrentasvir) in adults who are post primary orthotopic liver or renal transplant with chronic hepatitis C…
- Conditions
- Chronic Hepatitis C, HCV, Hepatitis C Virus
- Trial name
- NCT02692703
- Testing
- glecaprevir/pibrentasvir
- Volunteers
- 100 people
- Sponsor
- AbbVie
Hospital Mortality, Cancer
Death Certificate Analysis at Colombian Orinoquia: A Retrospective Observational Trial.
By hospital mortality, the health of a population is identified. Death certificates are a valuable tool in establishing causes of death.
- Conditions
- Hospital Mortality, Cancer, Chronic Disease, Non Communicable Chronic Diseases
- Trial name
- NCT05739305
- Testing
- Risk factor
- Where
- Colombia
- Volunteers
- 10,000 people
- Sponsor
- Hospital Departamental de Villavicencio
Hepatitis B, Chronic
Patients With Chronic Hepatitis B and Low Viremia Not Receiving Antiviral Therapy
This observational long-term follow-up study will evaluate demographic, clinical, histological, biochemical, and virological parameters of patients with chronic hepatitis B and low viremia who do not require antiviral therapy…
- Trial name
- NCT01090531
- Where
- 6 sites in Germany
- Volunteers
- 1,000 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Tobacco Cessation, Health Warning Label
Health Warnings and Counseling for Smoking Cessation
Tobacco use remains persistently high across South Asia, despite numerous public health efforts, and continues to significantly contribute to the burden of non-communicable diseases (NCDs) such as cardiovascular disease…
- Conditions
- Tobacco Cessation, Health Warning Label, Hypertension, Non Communicable Chronic Diseases
- Trial name
- NCT07098065
- Testing
- Graphical health warnings, Graphical health warnings plus pharmacist-led counselling, Routine pharmacy services (no intervention)
- Where
- Bangladesh
- Volunteers
- 3,400 people
- Sponsor
- Hitotsubashi University
Chronic Mental Illness, Chronic Physical Illness
Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project
The Wellness Incentives and Navigation (WIN) project is designed to help improve health self-management and reduce the incidence and consequences of chronic disease among non-elderly adult Medicaid Supplemental Security Income…
- Trial name
- WIN (NCT02440906)
- Testing
- Patient-Directed Wellness Account, Health Navigator
- Where
- United States
- Volunteers
- 1,663 people
- Sponsor
- University of Florida
Hepatitis C Virus (HCV)
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6…
- Trial name
- ENDURANCE-5 6 (NCT02966795)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 84 people
- Sponsor
- AbbVie
Cardiovascular Diseases, Non-Communicable Chronic Diseases
Intervention and Effect of Sleep Pattern on Cardio-cerebrovascular Disease
Because of the growing population of older people, cardio-cerebrovascular diseases has been the most important aging-related chronic disease, studying the pathogenesis and early warning mechanisms of cardio-cerebrovascular…
- Trial name
- NCT06294964
- Testing
- sleep education, behavioral education
- Where
- China
- Volunteers
- 12,800 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Nonalcoholic Fatty Liver Disease, Chronic Hepatitis b
Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）
This is a prospective, multicenter, open-label, non-randomized controlled real-world study to explore the efficacy and safety and to accumulate more evidence-based medical data of an antiviral treatment programme for chronic…
- Trial name
- NCT06368882
- Testing
- Peg-Interferon α
- Where
- 5 sites in China
- Volunteers
- 1,500 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
HIV-1-infection, Inflammation
The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events
MISTRAL (Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications, antimicrobial drug resistance, and unresponsiveness to therapeutic HIV-1 vaccination) is a 5-year EU Horizon…
- Conditions
- HIV-1-infection, Inflammation, AIDS
- Trial name
- MISTRAL (NCT05421286)
- Where
- 22 sites in Belgium, Croatia and 9 more
- Volunteers
- 991 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hepatitis C, Chronic
Eight Weeks of Elbasvir/Grazoprevir in the Treatment of HCV Genotype 4
To evaluate the safety and efficacy of a daily, fixed-dose, 8-week course combination of Elbasvir/Grazoprevir in treatment-naïve, non-cirrhotic patients who are mono-infected with hepatitis C, genotype 4.
- Trial name
- ELEGANT-4 (NCT03578640)
- Testing
- Elbasvir, Grazoprevir 50-100Mg Oral Tablet
- Where
- Saudi Arabia
- Volunteers
- 30 people
- Sponsor
- King Fahad Medical City
Hepatitis C, Liver Disease
Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option
The primary purpose of this study is to evaluate the pharmacodynamic (i.e. hepatitis C virus (HCV) viral load), pharmacokinetic and safety profiles between two treatment groups receiving different doses of DEB025 in combination…
- Trial name
- NCT02094443
- Testing
- Alisporivir, Ribavirin
- Where
- 16 sites in United States, France
- Volunteers
- 52 people
- Sponsor
- Debiopharm International SA
Hepatocellular Carcinoma (HCC), Chronic Hepatitis B
Post-Radical Treatment Antiviral Strategies in HBV-Related Liver Cancer: Impact on Tumor Prognosis
The goal of this clinical trial is to learn if peginterferon alfa-2b can reduce the recurrence of HBV-related liver cancer in patients who have undergone radical treatment.
- Trial name
- PRTRAS 001 (NCT07120750)
- Testing
- Intervention for Group 1, Intervention for Group 2
- Volunteers
- 332 people
- Sponsor
- Shenzhen Third People's Hospital
Hepatitis B Virus (HBV)
The Impact of Treatment for Chronic Hepatitis B Virus on Non-clinical Harms
The goal of this qualitative study is to explore the impact of antiviral treatment, or none, for chronic hepatitis B virus on the non-clinical (social) harms experienced by migrant populations living in the UK.
- Trial name
- B-SOCIAL (NCT07053449)
- Volunteers
- 30 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Chronic Hepatitis b
Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects
This is a single center, open-label, 3-Cohort, parallel, single-dose, study to evaluate the PK, safety, and tolerability of ATI-2173 50 mg administered orally in Japanese, Chinese, and Non-Asian healthy subjects incorporating a…
- Trial name
- NCT05298332
- Testing
- ATI-2173 50 mg
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Antios Therapeutics, Inc
Chronic Hepatitis C
Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.
The study is aimed to investigate the safety, tolerability and efficacy of a fixed dose combination therapy of: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (PEG-IFN alpha-2a) and Ribavirin (RBV) in Chronic Hepatitis C…
- Trial name
- NCT01272310
- Testing
- Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin
- Volunteers
- 36 people
- Sponsor
- Sheba Medical Center
Cardiovascular Diseases, COPD
The Cartagena Cohort Study
Cardiovascular and respiratory diseases are the first and third cause of death, respectively. Cardiovascular risk is known to increase in groups with impaired lung function; however, the mechanisms behind this association are not…
- Conditions
- Cardiovascular Diseases, COPD, Lung Function Decreased, Atherosclerosis
- Trial name
- CaReS (NCT05339048)
- Testing
- Genetic risk variants, Diet, Physical activity
- Where
- Colombia
- Volunteers
- 619 people, healthy volunteers welcome
- Sponsor
- Universidad de Cartagena